Destiny Pharma - C. difficile expert insight - discussion with Professor Gerding - 26 November 2021

Professor Dale Gerding is an expert on therapy for C.difficile whose work was recently recognised with a Lifetime Achievement award from the C Diff Foundation. Over the course of a detailed interview with Dr Andy Smith (analyst and microbiologist), Professor Gerding shares his latest thoughts on the growing threat posed by C diff. He also discusses the merits in its treatment shown by NTCD-M3, being developed by AIM-listed Destiny Pharma plc where Dale is a member of the Scientific Advisory Board.

You can watch the full video below (approximate length 43 minutes), divided into chapters for ease of viewing:

0:00     Introduction
0:51     History of CDIs
6:09    Clinical & commercial significance
11:51    Importance of the microbiome
17:53   Current / ideal standard of care
24:58  M3’s advantages over competition
29:01   Q&A